TELESIS BIO (TBIO)
(Real Time Quote from BATS)
$4.18 USD
+0.03 (0.72%)
Updated May 14, 2024 02:04 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TBIO]
Reports for Purchase
Showing records 41 - 60 ( 108 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q20 - COVID-19 Vaccine Trial Initiation in Humans Delayed
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Preclinical Data From COVID-19 and CF Programs Showcase Power of mRNA
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
COVID-19 Vaccine Shows Favorable Immunogenicity in Preclinical Testing
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
COVID-19 mRNA Vaccine Animal Data Show Signs of Immunogenicity
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Sanofi Collaboration Reinforces Pipeline Progress, MRT5005 Data Anticipated in 3Q20;
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Comprehensive Vaccine Collaboration Adds Further Validation to Differentiated mRNA Platform; Raising PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Industry: Medical - Drugs
Sanofi Vaccine Amendment Stretches to New Heights
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Vaccine Development Leverages Collaboration With Sanofi Amid Pandemic Impact on Pipeline; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Incremental Comments From Partner Sanofi on its COVID-19 mRNA Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T